Tema Etfs LLC Has $1.27 Million Stock Holdings in Celcuity, Inc. $CELC

by · The Markets Daily

Tema Etfs LLC increased its position in shares of Celcuity, Inc. (NASDAQ:CELC – Free Report) by 51.6% during the third quarter, Holdings Channel reports. The institutional investor owned 25,790 shares of the company’s stock after purchasing an additional 8,779 shares during the period. Tema Etfs LLC’s holdings in Celcuity were worth $1,274,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Soleus Capital Management L.P. grew its stake in Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after purchasing an additional 437,696 shares during the period. Eventide Asset Management LLC boosted its holdings in shares of Celcuity by 9.8% in the 2nd quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock worth $18,549,000 after buying an additional 123,774 shares during the last quarter. Saturn V Capital Management LP grew its position in Celcuity by 8.4% during the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after buying an additional 91,843 shares during the period. Ameriprise Financial Inc. increased its holdings in Celcuity by 27.6% during the second quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock worth $10,263,000 after buying an additional 166,324 shares during the last quarter. Finally, Captrust Financial Advisors raised its position in Celcuity by 2.3% in the second quarter. Captrust Financial Advisors now owns 570,441 shares of the company’s stock worth $7,615,000 after acquiring an additional 12,838 shares during the period. Institutional investors own 63.33% of the company’s stock.

Insider Transactions at Celcuity

In related news, Director Richard E. Buller sold 3,900 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the transaction, the director owned 7,260 shares in the company, valued at $702,259.80. This represents a 34.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 15.78% of the company’s stock.

Celcuity Stock Performance

NASDAQ:CELC opened at $104.51 on Tuesday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. Celcuity, Inc. has a fifty-two week low of $7.57 and a fifty-two week high of $112.64. The firm has a market cap of $4.84 billion, a PE ratio of -28.48 and a beta of 0.25. The business has a 50 day moving average price of $97.18 and a 200-day moving average price of $63.04.

Celcuity (NASDAQ:CELC – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.13. Equities research analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on CELC. HC Wainwright restated a “neutral” rating and issued a $94.00 price objective (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Wells Fargo & Company assumed coverage on shares of Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target on the stock. Wolfe Research started coverage on Celcuity in a research note on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective for the company. Craig Hallum boosted their target price on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Needham & Company LLC set a $95.00 price target on Celcuity in a report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Celcuity presently has an average rating of “Moderate Buy” and an average price target of $105.25.

Read Our Latest Stock Report on CELC

Celcuity Profile

(Free Report)

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

Recommended Stories

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC – Free Report).